Hun Lee, MD
Medical Oncology · Houston, TXNPI 1992930879
Payments from drug & device makers
Across 518 payments — averaging $29,633 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$8.2M
- Bristol Myers Squibb$2.8M
- Merck$2.5M
- Pfizer$1.1M
- AstraZeneca$366K
- E.r. Squibb & Sons, L.L.C.$210K
- plus $253K from 14 others
Across 8 payments — averaging $1052.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7K
- Bristol Myers Squibb$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 379 | $8,163,506 |
| Bristol Myers Squibb | 19 | $2,788,022 |
| Merck | 6 | $2,487,833 |
| Pfizer | 34 | $1,081,289 |
| AstraZeneca | 21 | $366,185 |
| E.r. Squibb & Sons, L.L.C. | 17 | $210,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $141,684 |
| Astrazeneca UK Limited | 2 | $103,556 |
| Genentech, Inc. | 1 | $3,000 |
| AbbVie | 12 | $1,490 |
| ADC Therapeutics America, Inc. | 2 | $1,361 |
| Beigene USA, Inc. | 6 | $661 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $170 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Beone Medicines USA, Inc. | 1 | $138 |
| Penumbra, Inc. | 1 | $134 |
| Regeneron Healthcare Solutions, Inc. | 1 | $115 |
| Genentech USA, Inc. | 2 | $113 |
| Johnson & Johnson | 1 | $28 |
| Amgen | 1 | $26 |
How this compares
$15,349,712 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
- Jenny ChangHouston$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.